Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD, and Safety of MT-1303 in Crohn's Disease
NCT02148185Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amiselimod in Crohn's disease, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Plasma concentration of MT-1303 up to 29 days and Plasma concentration of MT-1303 metabolite up to 29 days. Started May 2014; status: completed.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02148185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148185.